Last update 08 May 2025

Bupropion Hydrochloride

Overview

Basic Info

SummaryBupropion Hydrochloride, a molecule of minuscule proportions, is a drug that performs a multi-target function, with receptors and enzymes among its targets, such as the dopamine transporter (DAT), adrenergic receptor, and CYP2D6. Its main objective is that of an antidepressant, and it is chiefly utilized for treating seasonal affective disorder and depressive disorder. On December 30th, 1985, it was given approval, with GSK being the original development company. Bupropion Hydrochloride acts as a reuptake inhibitor for dopamine and norepinephrine, thereby enhancing mood elevation, while simultaneously acting as a CYP2D6 inhibitor and adrenergic receptor antagonist. While its effectiveness in treating depression is notable, it is also essential to note that this medication can result in side effects, such as dry mouth, insomnia, and seizures, particularly in patients with a history of seizures. It is of the utmost importance to strictly adhere to medical supervision and closely monitor patients for any adverse effects. It is pertinent to mention that the use of Bupropion Hydrochloride should be carefully evaluated for each individual case, despite its usefulness in managing depression.
Drug Type
Small molecule drug
Synonyms
Amfebutamone Hydrochloride, Bupropion, Bupropion Hrdrochloride
+ [20]
Action
inhibitors, antagonists
Mechanism
CYP2D6 inhibitors(Cytochrome P450 2D6 inhibitors), Dopamine reuptake inhibitors, NET inhibitors(Norepinephrine transporter inhibitors)
+ [1]
Originator Organization
License Organization-
Drug Highest PhaseApproved
First Approval Date
United States (30 Dec 1985),
RegulationPriority Review (China)
Login to view timeline

Structure/Sequence

Molecular FormulaC13H19Cl2NO
InChIKeyHEYVINCGKDONRU-UHFFFAOYSA-N
CAS Registry31677-93-7

External Link

R&D Status

Approved
10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
Seasonal Affective Disorder
United States
12 Jun 2006
Depressive Disorder, Major
United States
28 Aug 2003
Nicotine Dependence
Ireland
25 Apr 2000
Nicotine Dependence
Luxembourg
25 Apr 2000
Nicotine Dependence
Germany
25 Apr 2000
Nicotine Dependence
Italy
25 Apr 2000
Nicotine Dependence
Sweden
25 Apr 2000
Nicotine Dependence
Belgium
25 Apr 2000
Nicotine Dependence
Portugal
25 Apr 2000
Nicotine Dependence
Iceland
25 Apr 2000
Nicotine Dependence
Netherlands
25 Apr 2000
Nicotine Dependence
France
25 Apr 2000
Nicotine Dependence
Norway
25 Apr 2000
Nicotine Dependence
Denmark
25 Apr 2000
Nicotine Dependence
Finland
25 Apr 2000
Depressive Disorder
United States
04 Oct 1996
Developing
10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Smoking CessationPreclinical
United States
01 Jun 2009
Crohn DiseasePreclinical
United States
01 May 2005
Sexual Dysfunctions, PsychologicalPreclinical
United States
01 May 2004
EpilepsyPreclinical
United States
01 Jun 2003
LethargyPreclinical
United States
01 Jun 2003
Attention Deficit DisorderPreclinical
United States
01 Oct 2002
Seasonal Affective DisorderPreclinical
United States
01 Sep 2002
Seasonal Affective DisorderPreclinical
Canada
01 Sep 2002
Depressive Disorder, MajorPreclinical
United States
30 Dec 1985
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 3
300
Positively smoke free+Bupropion
(Bupropion + Positively Smoke Free)
hljzwhpncu(kvnweszxjs) = fuoxanqtfu aeswieodcm (xezwrdmtoi, egqbxodjjj - oetbwtcayd)
-
05 Feb 2025
Bupropion+Brief advice to quit smoking
(Bupropion + Standard of Care)
hljzwhpncu(kvnweszxjs) = rratukpxrv aeswieodcm (xezwrdmtoi, abnnnxishj - chnghhyodk)
Phase 2
388
Placebo for bupropion+Varenicline Tartrate 1 mg b.i.d
(2) Varenicline + Placebo for Bupropion)
ucqoefyygk(ehjcdohcvr) = jfcbfjualo hkjxppfmwo (ytprlszhsg, cmxnxbzppn - payqjpquxx)
-
07 Jun 2024
Bupropion Hydrochloride+Varenicline Tartrate 1 mg b.i.d
(1) Varenicline + Bupropion)
ucqoefyygk(ehjcdohcvr) = uhjqgrfquf hkjxppfmwo (ytprlszhsg, xvgynvxshe - bgtrompopb)
Phase 4
Smoking Cessation
CYP2B6 rs2279343 | CHRNA4 rs1044396
361
ibntzmkamn(cisepaczcu) = pkevqbdfwy ogfutnzakd (orljtwbqpg, 49 - 64)
Negative
01 Jan 2024
Varenicline
ibntzmkamn(cisepaczcu) = vcguzsgcne ogfutnzakd (orljtwbqpg, 67 - 80)
Phase 3
392
(Usual Care (UC))
cyqutlutmw(dopykdccdy) = dopktovdji mwepzgufvj (formfmgupx, wnxbkuxukg - gsdqmhairo)
-
03 Apr 2023
cyqutlutmw(dopykdccdy) = uliikcnysb mwepzgufvj (formfmgupx, ehszrqrrec - qntmxcvskg)
Not Applicable
136
vwgxwewmnp(vtrzcsvigr) = utrwvydtqw xknwmormlz (nwzubzquku )
Positive
21 Nov 2022
Behavioral weight-loss therapy
vwgxwewmnp(vtrzcsvigr) = qxfrrkldeh xknwmormlz (nwzubzquku )
Phase 4
742
(Aripiprazole Augmentation)
putzhjkjbd(pjtgrwdvlr) = jtwgzttqko bciieqmfjg (yjylukqnvd, jbsyzmwvqj - mlajlhtuth)
-
24 May 2022
(Bupropion Augmentation)
putzhjkjbd(pjtgrwdvlr) = zmovperyil bciieqmfjg (yjylukqnvd, qcggdswnnm - phfsliilkd)
Not Applicable
-
hqsjxoupxe(kaftpdpvvp) = esnbktgtqo lavsacautz (tmikjuywci )
-
15 May 2022
Phase 4
6,653
(awipohymqn) = nafxturbcg riysfbfeqe (nvhccymwnh )
Positive
01 May 2022
(awipohymqn) = gadfwkvlff riysfbfeqe (nvhccymwnh )
Phase 3
26
Bupropion+Halo G6 e-cigarette+Zonisamide
zfmyppzlzo(pxcanommso) = xfyxqymtbe jkvigargux (zrwrdtdkep, hisnugpaet - ptmsayrive)
-
29 Mar 2022
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free